Cargando…

178. Assessment of an IOTA (Intravenous to Oral Transition of Antimicrobial Therapy) in Gram Negative Bacteremias at a Community Teaching Hospital

BACKGROUND: Retrospective studies suggest that IV to oral therapy for gram-negative bacteremia has similar outcomes to IV regimens. The benefits of transitioning patients from IV to oral antibiotic therapy are well-recognized. The purpose of this study was to assess the percentage of patients (with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Victoria, Gardner, Sara R, Cady, Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679429/
http://dx.doi.org/10.1093/ofid/ofad500.251
Descripción
Sumario:BACKGROUND: Retrospective studies suggest that IV to oral therapy for gram-negative bacteremia has similar outcomes to IV regimens. The benefits of transitioning patients from IV to oral antibiotic therapy are well-recognized. The purpose of this study was to assess the percentage of patients (with a gram-negative bacteremia from a urinary source) who were transitioned from IV to oral antibiotics based on a pre-determined checklist. METHODS: This retrospective cohort study was performed at a 400-bed hospital from January 1, 2019 to May 31, 2022 . The primary objective was to assess the percentage of patients with a gram negative bacteremia (from a urinary source) who were eligible and switched from IV to oral antibiotics. Patients were included in the study if they were > 18 years old, had a positive blood culture for E. coli or K. pneumoniae (with > 1 susceptible oral antibiotic), had a monomicrobial infection from a urinary source, signs of clinical improvement, could tolerate oral medication, and had at least 24 hours of IV therapy. RESULTS: Sixty patients out of 200 (30%) with a gram negative bacteremia met the above eligibility criteria to be switched from IV to oral therapy. Sixty three percent (38/60) were switched to oral antibiotics for the completion of therapy. A majority of patients (95%) had E. coli bacteremia. Of the eligible patients, 70% (42/60) had received an ID consultation. Of those, 62% (26/42) were switched. Among the 18 eligible patients who did not receive an ID consult, 67% were switched to PO. Reasons for not switching (as determined from the EHR) for the 22 eligible patients include: 3 patients had pathogens resistant to fluoroquinolones, 8 had contraindications (unclear), 3 had concomitant infections, 7 had reasons unknown, and 1 patient denied oral antibiotics. CONCLUSION: Most patients (63%) who met inclusion criteria derived by previous studies were switched from IV to oral antibiotics in the presence of monomicrobial E. coli or Klebsiella pneumoniae bacteremia from a urinary source with clinical improvement. There is an opportunity to educate providers to transition more patients from IV to oral antibiotics with a gram negative bacteremia. DISCLOSURES: All Authors: No reported disclosures